Bausch + Lomb reports positive 24-month trial data for glaucoma treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma
March 23, 2026 7:00 AM EDTBoth primary effectiveness endpoints were met, demonstrating statistically significant and clinically meaningful intraocular pressure reduction. ELIOS is an implant-free procedure that uses excimer laser technology for the treatment of glaucoma. Topline results will be discussed at 1:30 p.m. ET today on the inaugural Bausch + Lomb R&D Teach-in Webinar (... More
